Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy

Nai-Bin Chen1†, Qi-Wen Li1,9†, Zheng-Fei Zhu4, Yi-Ming Wang5, Zhangkai J. Cheng1, Zhou-Guang Hui6,7, Su-Ping Guo1, Hao-Qiang He2, Bin Wang1, Xiao-Yan Huang1, Ji-Bin Li3, Jin-Yu Guo1, Nan Hu1, Xin-Lei Ai1, Yin Zhou8, Da-Quan Wang1, Fang-Jie Liu1, Chuan-Miao Xie9, Bo Qiu10† and Hui Liu1,9*.

Abstract

Purpose: The gross tumor volume (GTV) could be an independent prognostic factor for unresectable locally advanced non-small cell lung cancer (LANSCLC). We aimed to develop and validate a novel integrated GTV-TNM stratification system to supplement LANSCLC sub-staging in patients treated with concurrent chemoradiotherapy (CCRT).

Methods: We performed a retrospective review of 340 patients with unresectable LANSCLC receiving definitive CCRT. All included patients were divided into two randomized cohorts. Then the Kaplan–Meier method and Cox regression were calculated to access the prognostic value of the integrated GTV-TNM stratification system, which was further validated by the area under the receiver operating characteristic curve (AUC) score and F1-score.

Results: The optimal outcome-based GTV cut-off values (70 and 180 cm^3) of the modeling cohort were used to determine each patient’s integrated GTV-TNM stratum in the whole cohort. Our results indicated that a lower integrated GTV-TNM stratum could had better overall survival and progression-free survival (all \( P < 0.001 \)), which was recognized as an independent prognostic factor. Also, its prognostic value was robust in both the modeling and validation cohorts. Furthermore, the prognostic validity of the integrated GTV-TNM stratification system was validated by significantly improved AUC score (0.636 vs. 0.570, \( P = 0.027 \)) and F1-score (0.655 vs. 0.615, \( P < 0.001 \)), compared with TNM stage.
Introduction
Lung cancer remains the most common cancer worldwide with the highest cancer-related mortality [1] and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all these cases. The standard treatment of NSCLC depends primarily on the TNM staging system, which has been regarded as the single most prognostic factor in predicting survival outcomes of patients with lung cancer [2]. For patients with early stages diseases, surgical resection is recommended to be the primary therapy owing to its curative effect. The 5-year overall survival (OS) of these patients with complete resection ranges from 29 to nearly 90% [3, 4]. However, nearly 30% of patients with NSCLC have unresectable, locally advanced, stage III diseases, which nominated definitive concurrent chemoradiotherapy (CCRT) as principal treatment modality.

As is well known, stage III NSCLC represents a heterogeneous population, even within the same TNM stage following radical CCRT, there are large variations in survival outcome, suggesting that further pretreatment assessment beyond TNM stage may optimize treatment strategies and then improve clinical outcome. Several potentially important prognostic factors, specific for lung cancer treated with radiation therapy, have been identified, including performance status, weight loss, age, gender and histology [5]. In addition, tumor volume is a promising prognostic indicator revealed in numerous studies, which has been recognized in the carcinoma of head and neck, esophageal cancer, melanoma, breast cancer and cervical carcinoma treated with radiotherapy [6–10]. Previous radiobiological studies [11–14] have demonstrated that a larger tumor is related to more proliferation, hypoxia, and radio-resistance, which may compromise therapeutic effects. However, prognostic value of tumor volume in locally advanced non-small cell lung cancer (LANSCLC) has not yet been widely investigated.

It is generally considered that the current TNM staging system still has limitations, especially in the era of modern radiation technique. Simultaneous modulated accelerated radiation therapy (SMART) is widely used in LANSCLC and allows for precise dose delivery to the irradiated target, so that dose escalation can be achieved to improved disease control without excessive toxicity. The classical TNM staging depends mainly on operability, which focuses more on tumor size and location, and lacks quantitative volumetric evaluation of overall tumor burden. To date it has been difficult in a way to quantify tumor burden directly and accurately, which may restrict its application in clinical practice. With the advent of computerized planning systems for gross tumor target contouring and treatment planning in radiotherapy, data on gross tumor volume (GTV) can be available and systematically calculated. Thus, we launched a study to investigate prognostic value of GTV and TNM staging in unresectable LANSCLC treated with definitive CCRT, and then develop and validate an integrated GTV-TNM stratification system for clinical practice.

Materials and methods
Data collection
Consecutive patients diagnosed with unresectable LANSCLC who were treated with definitive CCRT at our institution between September 2011 and September 2018 were retrospectively screened. The entry criteria were as follows: (1) pathologically confirmed NSCLC; (2) inoperable stage III disease because of bulky primary disease (T3 or T4), mediastinal lymph node involvement (unresectable N2 or N3), or contraindication for surgical resection; (3) treated with radical radiotherapy (total radiation does ≥ 60 Gy) with concurrent chemotherapy; (4) without a history of prior chest radiotherapy; (5) Eastern Cooperative Oncology Group (ECOG) performance status score 0 to 2; (6) follow-up no less than 6 months since the start of radiotherapy unless death or tumor progression was documented. Those who met the above inclusion criteria in our two ongoing randomized clinical trials were enrolled in this analysis. All included patients were randomly divided, with a ratio of 2:1, into a training group and a validation group. Each patient received physical examination, electrocardiogram, pulmonary function test, laboratory tests, computed tomography (CT) scans of the chest and upper abdomen, brain magnetic resonance imaging (MRI), bone scan and/or positron emission tomography/computed tomography (PET/CT) and pathological biopsy. Tumor Staging was re-classified according to the TNM staging system proposed by the American Joint Committee on Cancer (8th edition) based on clinical work-ups.
Radical radiotherapy and GTV contouring
Patients were positioned supine and immobilized in a vacuum cradle. Using 4-dimensional computed tomography (4DCT) (Brilliance CT Big Bore, Philips), stimulation CT data sets scanning from the Atlas level to the second lumbar vertebra level with 5 mm thickness slices were obtained in 10 respiratory phases, and a maximum intensity projection (MIP) data set was constructed, which were then exported to the planning system (Monaco planning system, Elekta Medical Systems, Stockholm, Sweden) for target contouring and treatment planning. GTV, clinical target volume (CTV), planning target volume (PTV), and organs at risk (OARs) were delineated. The GTV included the primary tumor and positive regional lymph nodes, which were defined as nodes with a short-axis diameter no less than 1 cm on CT scan, or with high fluordeoxyglucose uptake on PET/CT scan, or pathologically approval by mediastinoscopy or endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA). For patients receiving neoadjuvant chemotherapy, the GTV was defined as the post-chemotherapy volume of initially determined primary tumor and positive regional lymph nodes. GTV-lung and GTV-node was contoured using pulmonary or mediastinal window CT settings, respectively. The CTV was defined as a 0.6 cm margin around GTV-lung, involved lymph node region and 1–2 elective stations. PTV-GTV and PTV-CTV was produced by expanding GTV and CTV with a 0.6 cm margin in all directions, respectively. Lungs, esophagus, spinal cord and heart were delineated as OARs. All contours were reviewed by a senior physician. All patients received SMART, using a 6–8 MV photon beam. A radiation dose of 60–70 Gy (2.0–3.0 Gy per fraction) was delivered to PTV-GTV, and 45–50 Gy (1.8–2.6 Gy per fraction) to PTV-CTV, in 24–33 fractions. At least 95% of PTV received 95% of prescribed dose. Dose constraints on the OARs were as follow: V20<35% for lungs; mean lung dose<1 Gy; maximum dose of esophagus<66 Gy; maximum dose of spinal cord<46 Gy; V30<30% for heart. Throughout the course of radiotherapy, weekly cone beam computed tomography (CBCT) was acquired before radiotherapy delivery for verification of the position of the tumor and OARs.

Concurrent chemotherapy
Platinum-based double agents were administered for concurrent chemotherapy in most patients. The regimens included docetaxel/ paclitaxel/ pemetrexed/ etoposide plus platinum, weekly or every 3 weeks. Several patients in clinical trial received triple agents as Nimotuzumab included. In patients with intolerance to double agents, single agent included pemetrexed, taxel or tyrosine kinase inhibitor (TKI) was allowed.

Follow-up and treatment response assessments
Each patient received a chest and upper abdomen CT scan every 3 months for the first 2 years after completion of CCRT, and subsequently every 6 months until tumor progression or death, while brain MRI was required every 6 months. PET/CT scan, bone scan, and biopsy were recommended if clinically suspected of progression. The responses to therapy were assessed by an independent radiation oncologist and confirmed by a senior physician at 1–2 months after radiotherapy based on Response Evaluation Criteria in Solid Tumors version 1.1. Disease progression was documented according to clinical, radiographic, or pathological evidence, and the first failure patterns were recorded. Disease recurrence at primary tumor site or local–regional lymph node was considered as locoregional recurrence, and all other sites of recurrence or metastases were defined as distant metastasis. OS and progression-free survival (PFS) were defined as the time from the initiation of radiotherapy to death, and the first occurrence of disease progression or death, respectively. The last follow up ended at May 1st, 2020. Therapeutic toxicities were recorded according to the National Cancer Institute Common Toxicity Criteria (version 4.0).

GTV risk group and the integrated GTV-TNM stratification system
The data on GTV were determined automatically from treatment planning system (TPS) using Zeus Cloud TPS V1.0 (Tongdiao, SuZhou, China). An X-tile analysis (Yale University, New Haven, CT, USA) provided the optimal outcome-based cut-off points to categorize patients into low GTV risk group (I), moderate GTV risk group (II) and high GTV risk group (III) in both the modeling and validation cohorts [15]. In order to optimize a novel integrated GTV-TNM stratification system, patients were classified into 9 subgroups: Group G1-IIIA (stage IIIA with GTV risk group I); Group G2-IIIA (stage IIIA with GTV risk group II); Group G3-IIIA (stage IIIA with GTV risk group III); Group G1-IIIB (stage IIIB with GTV risk group I); Group G2-IIIB (stage IIIB with GTV risk group II); Group G3-IIIB (stage IIIB with GTV risk group III); Group G1-IIIC (stage IIIC with GTV risk group I); Group G2-IIIC (stage IIIC with GTV risk group II); and Group G3-IIIC (stage IIIC with GTV risk group III). An ordered list of subgroups was constructed, relative to the best prognostic subgroup (Table 1). Several integrated stratification systems had been developed by combining similar subgroups [16, 17], and a final novel integrated
GTV-TNM stratification system comprising three strata was brought up, due to its statistical characteristics in the training cohort.

**Statistical analysis**

All eligible patients were randomized into a training cohort and a validation cohort with a ratio of 2:1. The distribution differences of categorical variables were examined with the Fisher’s exact test. Kaplan–Meier method was applied for survival analyses, which were compared by log-rank test (two-sided). Then those factors with a P value < 0.1 in the univariate analysis were incorporated into the Cox proportional hazards model to perform multivariate analysis for OS. A receiver operating characteristics (ROC) curve was produced for the integrated GTV-TNM stratification system, GTV risk group and TNM stage, and the area under ROC curve (AUC) was applied to assess the prognostic validity of these three different systems. Furthermore, bootstrap method was used to validate the predictions, which was done by randomly choosing 20% of the whole cohort for validation, and repeating 100 times to obtain a distribution of the prediction performance. For performance grading, F1 scores were calculated using Eq. 1–3 below:

\[
F_1 = 2 \times \frac{\text{precision} \times \text{recall}}{\text{precision} + \text{recall}}
\]

\[
\text{precision} = \frac{\text{TP}}{\text{TP} + \text{FP}}
\]

\[
\text{recall} = \frac{\text{TP}}{\text{TP} + \text{FN}}
\]

where TP is the true positive rate, FP is the false positive rate and FN is the false negative rate.

Statistical analyses were performed using SPSS 24.0 software (IBM, Chicago, IL, USA) and MATLAB® 2017 (MathWorks Inc., Massachusetts, USA), and the P value < 0.05 (two-sided) was considered as significant difference.

**Result**

**Baseline characteristics**

A total of 340 eligible patients were included in analysis. They were randomly assigned into a training group comprising 227 patients and a validation group with 113 patients. In the whole cohort, there were 64 females and 276 males with the median age of 58 (range from 28–81) years. There were 97 (28.5%) patients diagnosed with stage IIIA disease, 172 (50.6%) with stage IIIB and 71 (20.9%) with stage IIIC. For all patients, the median GTV volume was 101.0 (range, 9.1–664.3) cm³. In the training cohort, the optimal cutoff values of GTV in terms of OS were 71.2 cm³ and 177.2 cm³, which were determined by X-tile program. For the ease of clinical practice, we selected 70 cm³ and 180 cm³ as the uniform cutoff points in order to define patients into low, moderate and high GTV risk groups. GTV risk group I, II and III were defined as < 70 cm³, 70–180 cm³ and > 180 cm³, respectively. Docetaxel and platinum was the most commonly used regimen of concurrent chemotherapy (70.9%, 241/340). Most patients (254/340, 74.7%) received neo-adjuvant chemotherapy before definitive CCRT, and 21.8% patients (74/340) underwent adjuvant chemotherapy. All clinic-pathologic characteristics were similarly distributed between the training and validation groups (Table 2).

**Survival outcomes and tumor response**

The median follow-up was 28.9 (range, 1.5–103.4) months in all patients and 46.6 (range, 6.7–103.4) months in event-free patients. Our analysis depicted a median estimated OS of 44.7 months in all patients, 45.5 months in the training group, and 38.1 months in the validation group. The 3-year and 5-year OS rate was 59.9% and 44.1% in the training set, compared with 52.9% and 38.0% in the validation set (P = 0.283), respectively. The median estimated PFS was 12.1, 13.0, and 10.4 months in the whole cohort, training cohort and validation cohort. The 1-year and 2-year PFS rate was 52.7% and 31.9% in the training group, versus 44.9% and 25.6% in the validation group (P = 0.181), respectively.

In the training cohort, 10 patients had complete remission (CR), 154 had partial remission (PR), 49 had stable disease (SD) and 14 had progressive disease (PD). In the validation cohort, 6 patients had CR, 82 had PR, 18 had SD and 7 had PD. The objective response rate (ORR) was 74.1%, 72.2% and 77.9% in the whole, training and validation cohort, respectively (Additional file 1).
Table 3 summarized the results of univariate analysis of OS based on data from the training set and validation set. In the training set, GTV risk group (3-year OS, group I vs II vs III, 79.2% vs 56.8% vs 37.4%, $P < 0.001$) (Fig. 1a), ECOG score (3-year OS, ECOG 0 vs 1 vs 2, 68.2% vs 63.1% vs 33.1%, $P = 0.001$), weight loss $\geq 5$ kg (3-year OS, yes vs no, 38.7% vs 62.2%, $P = 0.018$) and age (3-year OS, $< 58$ years vs $\geq 58$ years, 66.8% vs 54.4%, $P = 0.088$) were significantly associated with OS, while TNM stage failed to reach statistical significance (3-year OS, stage IIIA vs IIIB vs IIIC, 58.7% vs 65.3% vs 49.7%, $P = 0.127$).

Table 2 Patients characteristics

| Characteristic                        | Training cohort n = 227 (%) | Validation cohort n = 113 (%) | $P$ value |
|---------------------------------------|-----------------------------|-------------------------------|-----------|
| Sex                                   |                             |                               | 0.659     |
| Male                                  | 186 (81.9)                  | 90 (79.6)                     |           |
| Female                                | 41 (18.1)                   | 23 (20.4)                     |           |
| Age (y)                               |                             |                               | $> 0.999$ |
| Median (range)                        | 59 (28–79)                  | 58 (31–81)                    | 0.126     |
| ECOG score                            |                             |                               |           |
| 0                                     | 29 (12.8)                   | 16 (14.2)                     |           |
| 1                                     | 170 (74.9)                  | 91 (80.5)                     |           |
| 2                                     | 28 (12.3)                   | 6 (5.3)                       |           |
| Weight loss $\geq 5$ kg               |                             |                               | 0.153     |
| Yes                                   | 23 (10.1)                   | 6 (5.3)                       |           |
| No                                    | 204 (89.9)                  | 107 (94.7)                    |           |
| Smoke index $\geq 400$                |                             |                               | 0.298     |
| Yes                                   | 129 (56.8)                  | 57 (50.4)                     |           |
| No                                    | 98 (43.2)                   | 56 (49.6)                     |           |
| Pathological types                    |                             |                               | 0.627     |
| Squamous cell carcinoma               | 130 (57.3)                  | 65 (57.5)                     |           |
| Adenocarcinoma                        | 80 (35.3)                   | 41 (36.3)                     |           |
| Lymphoepithelioma-like carcinoma      | 10 (4.4)                    | 5 (4.4)                       |           |
| Adenosquamous carcinoma               | 1 (0.4)                     | 1 (0.9)                       |           |
| Adenoid cystic carcinoma              | 2 (0.9)                     | 0 (0)                         |           |
| Large cell neuroendocrine carcinoma   | 0 (0)                       | 1 (0.9)                       |           |
| Giant cell carcinoma                  | 1 (0.4)                     | 0 (0)                         |           |
| Not otherwise specified(NOS)          | 3 (1.3)                     | 0 (0)                         |           |
| GTV (cm$^3$)                          |                             |                               | $> 0.999$ |
| Median (range)                        | 100.6 (9.1–664.3)           | 101.3 (10.5–567.7)            |           |
| GTV risk group                        |                             |                               | 0.993     |
| I ($< 70$ cm$^3$)                     | 65 (28.6)                   | 32 (28.3)                     |           |
| II (70–180 cm$^3$)                    | 119 (52.4)                  | 60 (53.1)                     |           |
| III ($> 180$ cm$^3$)                  | 43 (19.0)                   | 21 (18.6)                     |           |
| TNM stage                             |                             |                               | 0.978     |
| IIA                                    | 65 (28.6)                   | 32 (28.3)                     |           |
| IIIB                                   | 114 (50.2)                  | 58 (51.3)                     |           |
| IIIC                                   | 48 (21.2)                   | 23 (20.4)                     |           |
| Neoadjuvant chemotherapy              |                             |                               | 0.358     |
| Yes                                   | 166 (73.1)                  | 88 (77.9)                     |           |
| No                                    | 61 (26.9)                   | 25 (22.1)                     |           |
| Adjuvant chemotherapy                 |                             |                               | 0.127     |
| Yes                                   | 55 (24.2)                   | 19 (16.8)                     |           |
| No                                    | 172 (75.8)                  | 94 (83.2)                     |           |

ECOG, Eastern Cooperative Oncology Group; GTV, gross tumor volume

Risk factors for OS

Table 3 summarized the results of univariate analysis of OS based on data from the training set and validation set. In the training set, GTV risk group (3-year OS, group I vs II vs III, 79.2% vs 56.8% vs 37.4%, $P < 0.001$) (Fig. 1a), ECOG score (3-year OS, ECOG 0 vs 1 vs 2, 68.2% vs 63.1% vs 33.1%, $P = 0.001$), weight loss $\geq 5$ kg (3-year OS, yes vs no, 38.7% vs 62.2%, $P = 0.018$) and age (3-year OS, $< 58$ years vs $\geq 58$ years, 66.8% vs 54.4%, $P = 0.088$) were significantly associated with OS, while TNM stage failed to reach statistical significance (3-year OS, stage IIIA vs IIIB vs IIIC, 58.7% vs 65.3% vs 49.7%, $P = 0.127$).
In addition, neoadjuvant chemotherapy didn’t have tendency to improve OS (3-year OS, yes vs no, 59.6% vs 60.9%, \( P = 0.867 \)). Then these four variables reached \( P < 0.1 \) in univariate analysis were further analyzed by using multivariate Cox proportional hazards model. Multivariate analysis demonstrated significant increased risk of death in GTV risk group II (hazard ratio (HR), 1.71; 95% confidence interval (CI), 1.06–2.78; \( P = 0.030 \)) compared with group I, and ECOG score (\( P = 0.032 \)) was identified as another independent prognostic factor with HR of 1.61 (95% CI 1.04–2.49).

Similarly, in the validation group, univariate analysis revealed that patients with larger GTV (3-year OS, group I vs II vs III, 85.5% vs 46.4% vs 18.5%, \( P < 0.001 \)) (Fig. 1e), older age (3-year OS, < 58 years vs \( \geq 58 \) years, 62.2% vs 44.9%, \( P = 0.072 \)) (Fig. 1b), and ECOG score (\( P = 0.032 \)) were associated with worse OS. A multivariate Cox proportional hazards model was used to analyze the independent risk factors for survival. Table 3 demonstrates that the integrated GTV-TNM stratification system (\( P < 0.001 \)) was an independent risk factor for survival in both the training and validation cohorts.

### Table 3 Univariate analysis of risk factors for OS in the training cohort and validation cohort

| Factor                                      | Training cohort |                             | Validation cohort |                             |
|---------------------------------------------|-----------------|------------------------------|--------------------|------------------------------|
|                                             | 3-year OS (%)   | \( P \) value                | 3-year OS (%)      | \( P \) value                |
| Sex                                         | 0.100           |                              | 0.268              |                              |
| Male                                        | 57.9            |                              | 50.1               |                              |
| Female                                      | 69.6            |                              | 65.1               |                              |
| Age (y)                                     |                 |                              |                    |                              |
| < 58                                        | 66.8            | 0.088                        | 62.2               | 0.072                        |
| \( \geq 58 \)                                | 54.4            |                              | 44.9               |                              |
| ECOG score                                  | 0.001           |                              | 0.113              |                              |
| 0                                           | 68.2            |                              | 76.0               |                              |
| 1                                           | 63.1            |                              | 49.1               |                              |
| 2                                           | 33.1            |                              | 53.3               |                              |
| Weight loss \( \geq 5 \) kg                 |                 | 0.018                        | 0.308              |                              |
| Yes                                         | 38.7            |                              | 33.3               |                              |
| No                                          | 62.2            |                              | 54.1               |                              |
| Smoke index \( \geq 400 \)                  | 0.419           |                              | 0.087              |                              |
| Yes                                         | 56.8            |                              | 44.5               |                              |
| No                                          | 64.2            |                              | 62.0               |                              |
| Pathological types                          | 0.512           |                              | 0.521              |                              |
| Squamous cell carcinoma                     | 56.2            |                              | 60.1               |                              |
| Non-squamous cell carcinoma                 | 65.5            |                              | 59.4               |                              |
| GTV risk group                              |                 | \(< 0.001\)                  | \(< 0.001\)        |                              |
| I                                           | 79.2            |                              | 85.5               |                              |
| II                                          | 56.8            |                              | 46.4               |                              |
| III                                         | 37.4            |                              | 18.5               |                              |
| TNM stage                                   | 0.127           |                              | 0.297              |                              |
| IIIA                                        | 58.7            |                              | 59.6               |                              |
| IIIB                                        | 65.3            |                              | 49.5               |                              |
| IIIC                                        | 49.7            |                              | 53.2               |                              |
| The integrated GTV-TNM stratification system|                 | \(< 0.001\)                  | \(< 0.001\)        |                              |
| Stratum A                                   | 78.4            |                              | 82.4               |                              |
| Stratum B                                   | 63.7            |                              | 56.8               |                              |
| Stratum C                                   | 38.1            |                              | 24.7               |                              |
| Neoadjuvant chemotherapy                    | 0.867           |                              | 0.475              |                              |
| Yes                                         | 59.6            |                              | 56.1               |                              |
| No                                          | 60.9            |                              | 41.3               |                              |
| Adjuvant chemotherapy                       | 0.382           |                              | 0.713              |                              |
| Yes                                         | 55.7            |                              | 52.6               |                              |
| No                                          | 61.2            |                              | 52.9               |                              |

ECOG, Eastern Cooperative Oncology Group; GTV, gross tumor volume.

(Fig. 1b).
44.9%, P = 0.072) and smoke index ≥ 400 (3-year OS, yes vs no, 44.5% vs 62.0%, P = 0.087) had impaired OS. Again TNM stage (P = 0.297) (Fig. 1f) and neoadjuvant chemotherapy (P = 0.475) failed to predict OS. Only GTV risk group remained its statistical significance in multivariate analysis with HRs of 2.34 (95% CI 1.17–4.67; P = 0.016) and 6.27 (95% CI 2.78–14.16; P < 0.001) for group II and III relative to group I.

**Development and validation of a novel integrated GTV-TNM stratification system**

In order to optimize a prognostic sub-staging system for LANSCLC undergoing CCRT by integrating GTV risk group with the current TNM stage, nine subgroups were categorized and ordered as mentioned above, which eventually brought up a novel integrated GTV-TNM stratification system comprising three strataums (Table 4):

| GTV risk group | Stage IIIA | Stage IIIB | Stage IIIC |
|---------------|------------|------------|------------|
| GTV risk group I | Stratum A | Stratum A | Stratum B |
| GTV risk group II | Stratum B | Stratum B | Stratum C |
| GTV risk group III | Stratum C | Stratum C | Stratum C |

The integrated GTV-TNM stratification system (P < 0.001) significantly predicted OS in the training cohort, according to univariate analysis (3-year OS, Stratum A vs B, 78.4% vs 63.7%, P = 0.024; Stratum B vs C, 63.7% vs 38.1%, P = 0.002; Stratum A vs C, 78.4% vs 38.1%, P < 0.001) (Fig. 1c). Multivariate Cox regression analysis indicated increased risk of death in Stratum B (HR, 1.87; 95% CI 1.07–3.27; P = 0.028) and Stratum C (HR, 3.66; 95% CI 2.07–6.45; P < 0.001) compared with Stratum A, and ECOG score (P = 0.019) and weight loss ≥ 5 kg (P = 0.045) were independent prognostic factors of OS with HRs of 1.71 (95% CI 1.10–2.67) and 1.83 (95% CI 1.01–3.31), respectively (Additional file 2).

In the validation cohort, univariate Kaplan–Meier analysis demonstrated that the integrated GTV-TNM stratification system was statistically significantly associated with OS (3-year OS, Stratum A vs B, 82.4% vs 56.8%, P = 0.029; Stratum B vs C, 56.8% vs 24.7%, P = 0.001; Stratum A vs C, 82.4% vs 24.7%, P < 0.001) (Fig. 1g). Furthermore, the integrated GTV-TNM stratification system was recognized as the only independent prognostic factor for OS in multivariate analysis with HRs of 2.25 (95% CI 1.02–4.97; P = 0.045) and 5.62 (95% CI 2.46–12.80; P < 0.001) for Stratum B and C relative to Stratum A.

**The prognostic validity of the integrated GTV-TNM stratification system**

We used ROC curve to evaluate the prognostic validity of the integrated GTV-TNM stratification system, comparing with TNM stage and GTV risk group. In all patients, the AUC for OS was 0.636 (95% CI, 0.577–0.695) for the integrated GTV-TNM stratification system, versus 0.570 (95% CI, 0.509–0.631; P = 0.027) for TNM stage and 0.605 (95% CI, 0.545–0.665; P = 0.033) for GTV risk group (Fig. 2a). Bootstrap analysis demonstrated a significant increasing F1-scores in the integrated GTV-TNM stratification system (0.655 ± 0.052), compared to GTV risk group (0.638 ± 0.054, P = 0.013) and TNM stage (0.615 ± 0.056, P < 0.001), respectively (Fig. 2b).
First failure patterns and the prognosis of PFS
With a median follow-up of 28.9 months, a total of 238 patients exhibited failure, but 9 patients had no record of failure pattern. The most common type of first failure pattern is distant metastasis (58.0%, 192/331), while the rate of locoregional recurrence was 39.9% (132/331). Meanwhile, 25.1% (83/331) patients had synchronous failure experiencing distant metastasis and locoregional recurrence at the same time (Table 5). The integrated GTV-TNM stratification system had significant association with failure ($P = 0.018$) and distant metastasis ($P = 0.023$), and Stratum C had a higher risk to experience failure and distant metastasis.

In the prediction of PFS, univariate analysis showed that patients with higher stratum in the integrated GTV-TNM stratification system tended to have impaired PFS in both the training group (1-year PFS, Stratum A vs B vs C, 65.4% vs 46.6% vs 25.0%, $P < 0.001$) (Fig. 1d) and validation group (1-year PFS, Stratum A vs B vs C, 65.4% vs 46.6% vs 25.0%, $P < 0.001$) (Fig. 1h). Even though the prognosis failed to reach statistical significance when Stratum A vs Stratum B ($P = 0.097$ and $P = 0.176$, respectively), the integrated GTV-TNM stratification system could be a potential strong prognostic factor for PFS.

Therapeutic toxicities
The documented therapeutic toxicities were mostly grade 1 or 2. Forty-three cases (12.6%) of grade 3–5 acute pneumonitis were reported in our cohorts, including two patients with grade 5 pneumonitis. There were 16.5% of patients (56/340) developed grade 3–4 radiation esophagitis, and 17.9% patients (61/340) had grade 3–4 myeloctoxicity. The integrated GTV-TNM stratification system significantly correlated with Grade $\geq 3$ pneumonitis ($P = 0.026$), and Stratum C had a higher risk to develop Grade $\geq 3$ pneumonitis (Table 6).

Table 5 The distribution of first failure patterns among patients with the integrated GTV-TNM stratification system in the whole cohort

| The integrated GTV-TNM stratification system | Locoregional recurrence (%) | $P$ value | Distant metastasis (%) | $P$ value | Synchronous failure (%) | $P$ value | Total (%) | $P$ value |
|---------------------------------------------|----------------------------|-----------|------------------------|-----------|-------------------------|-----------|-----------|-----------|
| Stratum A ($n = 79$)                        | 28 (35.4)                 | 0.393     | 40 (50.6)              | 0.023     | 18 (22.9)               | 0.222     | 50 (63.3) | 0.018     |
| Stratum B ($n = 157$)                       | 61 (38.9)                 |           | 86 (54.8)              |           | 35 (22.3)               |           | 110 (70.1) |           |
| Stratum C ($n = 95$)                        | 43 (45.3)                 |           | 66 (69.5)              |           | 30 (31.6)               |           | 78 (82.1) |           |
| Total ($n = 331$)$^*$                       | 132 (39.9)                |           | 192 (58.0)             |           | 83 (25.1)               |           | 238 (71.9) |           |

$^*$ 9 patients had no record of failure pattern, but their deaths were documented, thus a total of 331 patients were enrolled in this analysis of first failure patterns

GTV, gross tumor volume


Table 6 Grade ≥ 3 therapeutic toxicities among patients with the integrated GTV-TNM stratification system in the whole cohort

| The integrated GTV-TNM stratification system | Toxicities | Grade ≥ 3 pneumonitis (%) | P value | Grade ≥ 3 esophagitis (%) | P value | Grade ≥ 3 myelotoxicity (%) | P value |
|---------------------------------------------|------------|---------------------------|---------|---------------------------|---------|---------------------------|---------|
| Stratum A (n = 79)                           |            | 7 (9.0)                   | 0.026   | 10 (12.7)                 | 0.395   | 15 (19.0)                 | 0.857   |
| Stratum B (n = 162)                          |            | 16 (9.9)                  |         | 26 (16.0)                 |         | 30 (18.5)                 |         |
| Stratum C (n = 99)                           |            | 20 (20.2)                 |         | 20 (20.2)                 |         | 16 (16.2)                 |         |
| Total (n = 340)                              |            | 43 (12.6)                 |         | 56 (16.5)                 |         | 61 (17.9)                 |         |

**Discussion**

Our results demonstrate that the prognostic stratification system integrated GTV with TNM staging has provided greater predictive value for survival outcomes in unresectable LANSCLC patients receiving definitive CCRT. To our best knowledge, it is the first study to propose an integrated GTV-TNM stratification system and depict its prognostic value, with the largest sample size to date.

The current study used the optimal outcome-based GTV cutoff points (70 and 180 cm$^3$) of the modeling cohort to determine each patient’s GTV risk group. Our results suggested that GTV was a strong prognostic factor in unresectable LANSCLC, which were consistent with previous studies [18–20]. Then we established a novel integrated GTV-TNM stratification system, which was examined in the modeling and validation cohorts using Kaplan–Meier method and Cox regression. The univariate analysis indicated that the integrated GTV-TNM stratification system significantly predicted OS in the training cohort (3-year OS, Stratum A vs B, 78.4% vs 63.7%, P = 0.024; Stratum B vs C, 63.7% vs 38.1%, P = 0.002; Stratum A vs C, 78.4% vs 38.1%, P < 0.001). Multivariate Cox regression analysis showed an increased risk of death in Stratum B (HR, 1.87; 95% CI 1.07–3.27; P = 0.028) and Stratum C (HR, 3.66; 95% CI 2.07–6.45; P < 0.001) compared with Stratum A. In the prediction of PFS, patients with higher stratum in the integrated GTV-TNM stratification system tended to have impaired PFS (P < 0.001). Such statistical significance could achieve in the validation group equally. The results were robust in these two randomized sets, suggesting that the integrated GTV-TNM stratification system may be able to generalize to the general population.

Several clinical and pathological characteristics have been considered as prognostic factors for survival outcomes. Recently multiple published studies have demonstrated that pretreatment tumor burden measured by PET/CT scan was highly correlated with treatment outcomes in LANSCLC patients receiving definitive CCRT [21–23]. Bradley et al. [18] concluded that GTV determined by three-dimensional conformal radiotherapy (3DCRT) planning had great prognostic value for long-term survival and local control. In the secondary analysis of the Radiation Therapy Oncology Group (RTOG) 93-11, Werner-Wasik et al. [19] reported that an increasing GTV was strongly associated with poor OS and PFS. In addition, Basaki et al. [20] suggested that GTV included primary tumor volume and positive lymph nodes, could provide better prognostic value for survival outcomes than TNM stage alone, which was consistent with several published reports [24, 25] and the present study. Moreover, the relationship between tumor volume and tumor control probability for NSCLC, breast tumor, head and neck cancer, malignant melanoma, and cervical carcinoma had been extensively investigated by clinical data as well as radiobiologic models [26–29]. However, the majority of those studies were conducted retrospectively, and several published data didn’t support the prognostic value of tumor volume [30–32]. Ball et al. [33] launched a multicenter prospective observational study to investigate the prognostic value of primary tumor volume in stage I-III NSCLC treated by definitive radiotherapy. They concluded that primary tumor volume failed to provide additional prognostic information after adjusting for the effects of the T and N stages. This may indicate that making prognosis with tumor volume alone is not adequate. Our results suggested GTV was an independent prognostic factor. The AUC the prediction of for OS was 0.636 for the integrated GTV-TNM stratification system, versus 0.570 for TNM stage (P = 0.027) and 0.605 for GTV risk group (P = 0.033), which implied tumor volume alone was not sufficient for prediction of LANSCLC patients after CCRT.

Therefore, TNM staging for LANSCLC remains useful for classifying the extent of spread of cancer, while GTV appears to be a crucial factor for CCRT. Although TNM staging is more commonly regarded as a classification system of anatomical extent of tumor, it provides great details of the spread route of lung cancer. In TNM staging, the “T” classification comprises the size, location
and extent of the primary tumor, while the “N” classification represents lymph node involvement, indicating whether or not the lymph nodes are infiltrated and the involved lymph node region and station. It could perfectly illustrate the relationship between primary tumor and involved lymph nodes in LANSCLC. It would be more practical to integrate the GTV information into the current TNM classification system than GTV risk group or TNM staging alone in LANSCLC patients treated with CCRT. The integration would effectively guide the clinical management and develop better treatment approaches for this subgroup of patients. Other than that, intensity-modulated radiotherapy (IMRT), especially SMART technique, has become the leading radiotherapy technique of lung cancer substituting for 3DCRT. SMART technique was used to deliver different prescription doses to GTV and CTV simultaneously, which afforded dose escalation to GTV and sparing of surrounding tissues. Furthermore, treatment planning in radiotherapy is currently conducted on specialized computerized planning system, which could enable exact location, definition and quantification of tumor volume.

The ROC curve results suggested that the prognostic validity could be increased by integrating the current TNM staging system with GTV. Analysis using the ROC curve is typically more suitable for models using continuous predictor for survival outcome, whereas in our study, the predictor used is discrete (either Stratum B or Stratum C). Thus we employ a more suitable index, i.e. F1-score, which makes full use of precision and recall (or sensitivity) to evaluate the model performance, and is routinely used in the field of computer science. In our study, F1-score was significantly higher in the integrated GTV-TNM stratification system and indicated a superior prognostic value comparable to TNM stage and GTV risk group alone in LANSCLC patients treated with definitive CCRT.

It was well recognized that consolidation chemotherapy failed to yield significant survival benefit for unresectable LANSCLC [34–38]. However, based on the series results of the phase III PACIFIC study and other phase II trials [39–41], consolidation immunotherapy following CCRT significantly improve PFS and OS with acceptable toxicities in these patients, establishing a new standard of care. In PACIFIC trial, the PFS curve of durvalumab group plateaued at a proportion surviving of 40%, indicating that certain subpopulation could achieve a potential cure. In addition, compared with placebo, a higher incidence of pneumonitis or radiation pneumonitis of any grade occurred in patients receiving durvalumab (33.9% vs. 24.8%), but the rate of grade 3 or 4 was similar (3.4% vs. 2.6%). To be noticed, Asian patients seemed to have a higher incidence of any grade pneumonitis (73.6%) and severe pneumonitis (5.6%). Identifying the high-risk subgroup early is essential for the decision of consolidation immunotherapy, based on the concept of individualized treatment. Our results indicated that patients with the integrated GTV-TNM stratification system Stratum C had a higher risk to develop severe pneumonitis. Therefore, because of the lung injury following large-volume irradiation, consolidation immunotherapy might not be safely administered in Stratum C patients, which deserves further investigation.

Honestly, there were several limitations existed in our retrospective study. Firstly, it was a study comprised patients from 2 clinical trials and daily clinical practice, thus the concurrent chemotherapy regimens were determined by specific protocols and individual patient management. Secondly, the cut-off values for GTV risk group and the integrated GTV-TNM stratum were identified from a single center. Despite the distribution of TNM stages in our analysis seems to be consistent to the global sample [16], larger external databases are warranted to validate the optimal cut-off values for the general population of LANSCLC patients.

Conclusions
We proposed a novel integrated GTV-TNM stratification system to supplement unresectable LANSCLC sub-staging due to its prognostic value independent of TNM stage and other clinical characteristics, suggesting that it could be considered in individual treatment decision-making process.

Supplementary information

Additional file 1. Tumor response.
Additional file 2. Multivariate analysis of the prognosis of the integrated GTV-TNM stratification system in the training cohort and validation cohort.

Abbreviations
GTV: Gross tumor volume; LANSCLC: Locally advanced non-small cell lung cancer; CCRT: Concurrent chemoradiotherapy; AUC: Area under the receiver operating characteristic curve; NSCLC: Non-small cell lung cancer; OS: Overall survival; SMART: Simultaneous modulated accelerated radiation therapy; ECOG: Eastern Cooperative Oncology Group; CT: Computed tomography; MRI: Magnetic resonance imaging; PET/CT: Positron emission tomography/computed tomography; 4DCT: 4-Dimensional computed tomography; MIP: Maximum intensity projection; CTV: Clinical target volume; PTV: Planning target volume; OAR: Organ at risk; EBUS-TBNA: Endobronchial ultrasound-transbronchial needle aspiration; CBCT: Cone beam computed tomography; TKI: Tyrosine kinase inhibitor; PFS: Progression-free survival; TPS: Treatment planning system; ROC: Receiver operating characteristics; CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; HR: Hazard ratio; CI: Confidence interval; RTOG: Radiation Therapy Oncology Group; IMRT: Intensity-modulated radiotherapy.

Acknowledgements
Not applicable.
Authors' contributions

All authors should have made substantial contributions to all of the following: (1) HL and BQ contributed to the conception and design of the study. (2) NBC, QWL, ZFZ, YMW, ZKC, ZGH, SPG, HQH, BW, XYH, JYG, NH, XLA, DQW, FJL and CNX contributed to acquisition of data. (3) NBC, QWL, ZFZ, YMW, ZKC, ZGH, JBL and YZ analyzed and interpreted data. (4) NBC and QWL drafted the article. (5) HL and BQ made the final approval of the version to be submitted. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was reviewed and approved by the Ethics Committee of Sun Yat-Sen University Cancer Center. As its retrospective nature, a waiver of written informed consent was granted.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, People’s Republic of China. 2 Medical Imaging, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China. 3 Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China. 4 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China. 5 Department of Radiation Oncology, The First Affiliated Hospital of Jinan University, Guangzhou, People’s Republic of China. 6 Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China. 7 VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China. 8 Evidence Medical Technologies Inc., Ningbo, People’s Republic of China. 9 Lung Cancer Institute, Sun Yat-Sen University, Guangzhou, People’s Republic of China.

Received: 11 September 2020   Accepted: 30 October 2020

Published online: 10 November 2020

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
2. Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, We Blum P et al. The IASLC lung cancer staging Project: proposals for the M descriptors and for revision of the Tnm stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:2112–9.
3. Endo C, Sakurada A, Notsuda H, Noda M, Hoshikawa Y, Okada Y et al. Results of long-term follow-up of patients with completely resected non-small cell lung cancer. Ann Thorac Surg. 2012;93:1061–8.
4. Yamamoto K, Ohsumi A, Kojima F, Imanishi N, Matsuoka K, Ueda M et al. Long-term survival after video-assisted thoracic surgery lobectomy for primary lung cancer. Ann Thorac Surg. 2010;89:533–9.
5. Jeremic B, Milicic B, Milisavljevic S. Clinical prognostic factors in patients with locally advanced (stage III) non-small cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients. Cancer. 2011;117:2995–3003.
6. Kneppens JL, Hauptmann M, Pameijeier FA, Balm AJ, Hoebers FJ, de Bois JA et al. Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head Neck. 2011;33:375–82.
7. Guo R, Sun Y, Yu XL, Yin WJ, Li WF, Chen YY et al. Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol. Eur Soc Ther Rad Oncol. 2012;104:294–9.
8. Chen MK, Chen TH, Liu JP, Chang CC, Chie WC. Better prediction of prognosis for patients with nasopharyngeal carcinoma using primary tumor volume. Cancer. 2004;100:2160–6.
9. Chen J, Lin Y, Cai W, Su T, Wang B, Li J et al. A new clinical staging system for esophageal cancer to predict survival after definitive chemoradiation or radiotherapy. Dis Esophagus Off J Int Soc Dis Esophagus. 2018. https://doi.org/10.1093/dote/doy043.
10. Mendenhall WM, Sombread MD, Freeman DE, Morgan LS. Stage IB and IIA-B carcinoma of the intact uterine cervix: impact of tumor volume and the role of adjuvant hysterectomy. Semin Radiat Oncol. 1994;4:16–22.
11. Johnson CR, Thames HD, Huang DT, Schmidt-Ullrich RK. The tumor volume and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys. 1995;33:281–7.
12. Okunieff P, Hoedel M, Dunphy EP, Schlenger K, Knoop C, Vaupel P. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys. 1993;26:631–6.
13. Larntigau E, Le Ridant AM, Lambin P, Weeger P, Martin L, Sigal R et al. Oxygenation of head and neck tumors. Cancer. 1993;71:2319–25.
14. Yes PJ. Tumor heterogeneity, tumor size, and radioresistance. Int J Radiat Oncol Biol Phys. 1993;26:631–6.
15. Camp RL, Dilled-Fi hellart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10:7252–9.
16. Goldstraw P, Chansky K, Crowley J, Ramí-Porta R, Asahara H, Eberhardt WE et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.
17. Goldstraw P, Crowley J, Chansky K, Gioreux DJ, Groome PA, Ramí-Porta R et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.
18. Bradley JD, Jemalwannanontchali N, Purdy JA, Wasserman TH, Lockett MA, Graham MV et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:49–57.
19. Werner-Wasik M, Swann RS, Bradley J, Graham M, Emami B, Purdy J et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93–11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:385–90.
20. Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys. 2006;64:449–54.
21. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in non-surgical patients with non-small cell lung cancer. Eur J Nuclear Med Mol Imaging. 2012;39:27–38.
22. Ohri N, Duan F, Machty M, Gorelik JJ, Snyder BS, Alavi A et al. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer. ACRIN 6668/RTDG O23S. J Natl Cancer Inst. 2015;107:diy004.
23. Pu Y, Zhang JX, Liu H, Appelbaum D, Meng J, Penney BC. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. Eur J Nuclear Med Mol Imaging. 2018;45:2079–92.

24. Dehing-Oberije C, van der Weide H, Hochstenbag M, Bootma G, Geraedts W, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1039–44.

25. Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, et al. Development and validation of prognostic model for 2-year survival of non-small cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;74:355–62.

26. Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:382–9.

27. Bentzen SM, Thames HD. Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys. 1993;26:171–9.

28. Bentzen SM, Thames HD. Tumor volume and local control probability: mathematical models. Int J Radiat Oncol Biol Phys. 1997;37:913–20.

29. Wu PM, Chua DT, Sham JS, Leung L, Kwong DL, Lo M, et al. Tumor control prediction in primary radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:1039–44.

30. Andratschke N, Zimmermann F, Boehm E, Schill S, Schoenknecht C, Thamm R, et al. Stereotactic radiotherapy of histologically proven inoperable stage III non-small cell lung cancer. J Surg Oncol. 2015;112:175–81.

31. Janssens GO, van Bockel LW, Doornaert PA, Bijl HP, van den Ende P, de Jong MA, et al. Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial. Eur J Cancer (Oxf, Engl, 1990). 2014;50:1112–9.

32. Timmermans AJ, Lange CA, de Bois JA, van Werkhoven E, Hamming-Vriese O, Hilgers FJ, et al. Tumor volume as a prognostic factor for local control and overall survival in advanced larynx cancer. Laryngoscope. 2016;126:E60–7.

33. Ball DL, Fisher RJ, Burmeister BH, Poulsen MG, Graham PH, Penninnett MG, et al. The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05). Radiother Oncol Eur Soc Ther Radiol Oncol. 2013;106:305–11.

34. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIb non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:2004–10.

35. Hanno N, Neubauer M, Yannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:5735–60.

36. Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSC-LU05-04. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2660–6.

37. Carter DL, Garfield D, Hathorn J, Mundis R, Boehm KA, Ilegbudu D, et al. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel as observation for patients with locally advanced inoperable non-small-cell lung cancer. Clin Lung Cancer. 2012;13:205–13.

38. Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol. 2015;10:1811–9.

39. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–29.

40. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379:2342–50.

41. Durr GA, Jabbour SK, Althouse SK, Liu Z, Sadig AA, Zon RT, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14–179. Cancer. 2020. https://doi.org/10.1002/cncr.33083.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.